The stock price of C4 Therapeutics Inc (NASDAQ: CCCC) has jumped by 6.86 compared to previous close of 3.50. Despite this, the company has seen a fall of -8.56% in its stock price over the last five trading days. zacks.com reported 2025-01-02 that C4 Therapeutics (CCCC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?
Company’s 36-month beta value is 2.97.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for CCCC is 56.91M, and currently, short sellers hold a 15.12% ratio of that floaft. The average trading volume of CCCC on January 15, 2025 was 1.42M shares.
CCCC’s Market Performance
CCCC’s stock has seen a -8.56% decrease for the week, with a -20.59% drop in the past month and a -31.50% fall in the past quarter. The volatility ratio for the week is 7.91%, and the volatility levels for the past 30 days are at 8.75% for C4 Therapeutics Inc The simple moving average for the last 20 days is -3.39% for CCCC’s stock, with a simple moving average of -33.07% for the last 200 days.
Analysts’ Opinion of CCCC
Many brokerage firms have already submitted their reports for CCCC stocks, with Wells Fargo repeating the rating for CCCC by listing it as a “Overweight.” The predicted price for CCCC in the upcoming period, according to Wells Fargo is $12 based on the research report published on December 19, 2024 of the previous year 2024.
Stephens, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $4. The rating they have provided for CCCC stocks is “Equal-Weight” according to the report published on November 18th, 2024.
JP Morgan gave a rating of “Neutral” to CCCC, setting the target price at $6 in the report published on January 29th of the previous year.
CCCC Trading at -15.38% from the 50-Day Moving Average
After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.52% of loss for the given period.
Volatility was left at 8.75%, however, over the last 30 days, the volatility rate increased by 7.91%, as shares sank -13.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.37% lower at present.
During the last 5 trading sessions, CCCC fell by -8.56%, which changed the moving average for the period of 200-days by -53.54% in comparison to the 20-day moving average, which settled at $3.87. In addition, C4 Therapeutics Inc saw 3.89% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CCCC starting from Salter Malcolm, who proposed sale 13,000 shares at the price of $4.19 back on Nov 18 ’24. After this action, Salter Malcolm now owns shares of C4 Therapeutics Inc, valued at $54,532 using the latest closing price.
Salter Malcolm, the Director of C4 Therapeutics Inc, proposed sale 13,000 shares at $6.41 during a trade that took place back on Oct 18 ’24, which means that Salter Malcolm is holding shares at $83,321 based on the most recent closing price.
Stock Fundamentals for CCCC
Current profitability levels for the company are sitting at:
- -3.54 for the present operating margin
- 0.77 for the gross margin
The net margin for C4 Therapeutics Inc stands at -3.13. The total capital return value is set at -0.36. Equity return is now at value -46.00, with -29.76 for asset returns.
Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.06.
Currently, EBITDA for the company is -122.1 million with net debt to EBITDA at -0.08. When we switch over and look at the enterprise to sales, we see a ratio of 8.06. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.31.
Conclusion
In a nutshell, C4 Therapeutics Inc (CCCC) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
